The Latest Breaking News from MAPS

Continued digital transformation should propel the demand for software-as-a-service (SaaS) solutions across various industries. Therefore, since the macroeconomic and geopolitical issues have led to quality SaaS stocks WM Technology (MAPS), The Sage Group (SGPYY), and The Descartes Systems (DSGX) witnessing a significant decline lately, these stocks could be ideal additions…

Mental Health Awareness Week is highlighting support available for people worried about handling their finances.

As reported during its first-quarter 2022 earnings call, WM Technology Inc (NASDAQ: MAPS), d.b.a. Weedmaps, has completed the acquisition of cannabis-focused digital menu and ad company Enlighten.

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock.  In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy. 

Google lets you prioritize fuel-efficient routes, shows bike and train information for alternatives, helps you find charging stations for your EV, and more. Here's how to save gas (and the environment) and be more eco-friendly when on the go with Google Maps.

The software industry is expected to grow tremendously in the coming months, thanks to accelerating digitalization and technology dependence amid continuing remote lifestyles. Thus, we think it could be wise to invest now in fundamentally solid small-cap software stocks CSG Systems (CSGS), WM Technology (MAPS), and Benefitfocus (BNFT).

Hundreds of P&O Ferries workers laid off last month are in danger of switching their retirement funds into less generous alternatives, financial experts are warning

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research isn’t enough to convince you, then two more crucial factors surely will. Firstly, a new ‘accelerated pathway’ has…

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.